Article
Clinical Neurology
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Haenni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Oezguer Yaldizli
Summary: In a real-world setting, dimethyl fumarate and fingolimod demonstrate comparable effectiveness in reducing relapses and disability worsening in patients with RRMS. Findings from this study suggest that there is no significant difference in efficacy between the two treatment options, regardless of whether patients are treatment-naive or switching from another DMT.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Jannis Muller, Sabine Schadelin, Johannes Lorscheider, Pascal Benkert, Peter Hanni, Jurg Schmid, Jens Kuhle, Tobias Derfuss, Cristina Granziera, Ozgur Yaldizli
Summary: This study compared the effectiveness of dimethyl fumarate (DMF) and teriflunomide in a real-world setting and found that DMF treatment was associated with better clinical outcomes.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Raed Alroughani, Peter Huppke, Maria Mazurkiewicz-Beldzinska, Astrid Blaschek, Martin Valis, Gregory Aaen, Joe Pultz, Xiaomei Peng, Vanessa Beynon
Summary: The CONNECTED study found that long-term treatment with delayed-release dimethyl fumarate (DMF) in pediatric MS patients was safe and effective, with results consistent with adults, suggesting potential benefits for pediatric and adolescent MS patients.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
E. Tsantes, E. Curti, D. Ferraro, A. Lugaresi, E. Baldi, S. Montepietra, P. Immovilli, A. M. Simone, L. Mancinelli, S. Strumia, F. Vitetta, M. Foschi, C. Ferri, C. Ferrarini, P. Sola, F. Granella
Summary: In patients with multiple sclerosis, a decrease in lymphocyte count after 6 months of DMF treatment is associated with better outcomes. A greater reduction in lymphocyte count is linked to a lower risk of losing NEDA-3 status.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Luca Prosperini, Shalom Haggiag, Serena Ruggieri, Carla Tortorella, Claudio Gasperini
Summary: Based on real-world studies, we found that dimethyl fumarate (DMF) is slightly more effective than teriflunomide (TRF) in reducing the short-term relapse risk of relapsing-remitting multiple sclerosis. However, there were no significant differences in reducing confirmed disability worsening and treatment discontinuation between the two drugs.
Article
Clinical Neurology
Karolina Kania, Wojciech Ambrosius, Wojciech Kozubski, Alicja Kalinowska
Summary: Balo's concentric sclerosis (BCS) is a rare demyelinating disorder with a debated connection to classic multiple sclerosis. Our report presents a case of a patient who developed a symptomatic Balo-like lesion following years of treatment for relapsing-remitting multiple sclerosis with dimethyl fumarate.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Kunio Nakamura, Oksana Mokliatchouk, Douglas L. Arnold, Tarek A. Yousry, Ludwig Kappos, Nancy Richert, Katherine Ayling-Rouse, Catherine Miller, Elizabeth Fisher
Summary: Reanalysis of MRI images from the DEFINE/CONFIRM trials showed that dimethyl fumarate (DMF) reduces brain volume loss in the second year compared to placebo, consistent with its effects on relapses, disability, and MRI lesions in patients with multiple sclerosis (MS). The brain volume changes in the first year may be explained by pseudoatrophy effects observed in other MS clinical trials.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Stanley Cohan, Jinender Kumar, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic, Tom Tencer
Summary: This study compared the efficacy and safety of ozanimod and dimethyl fumarate (DMF) for multiple sclerosis using a matching-adjusted indirect comparison method. The results suggested that ozanimod showed greater reduction in relapses, lower risk of disability progression at 3 months, and improved safety outcomes compared to DMF. However, limitations include potential confounding due to unobserved baseline differences, highlighting the need for head-to-head treatment comparisons in randomized clinical trials.
Article
Clinical Neurology
Naoya Saijo, Yu Abe, Yoshitsugu Oikawa, Yukimune Okubo, Wakaba Endo, Yurika Numata-Uematsu, Toshiyuki Takahashi, Mitsugu Uematsu
Summary: DMF may be a useful oral disease-modifying drug for preventing recurrence in young children with MS.
BRAIN & DEVELOPMENT
(2022)
Article
Clinical Neurology
Lilyana Amezcua, Yang S. Mao-Draayer, Wendy Vargas, Rebecca Farber, Sara Schaefer, Filipe M. Branco, Sarah England, Nicholas B. Belviso, James P. Lewin, Jason L. Mendoza, Sai Shankar, ENDORSE Study Investigators
Summary: This study evaluated the safety and efficacy of dimethyl fumarate (DMF) in a subgroup of young adults aged 18-29 years with multiple sclerosis (MS). The results showed that DMF had a favorable benefit-risk profile in young adults, with well-characterized safety, sustained efficacy, and stable patient-reported outcomes (PROs) over a 13-year follow-up period.
NEUROLOGY AND THERAPY
(2023)
Article
Medicine, General & Internal
Bahadar S. Srichawla
Summary: This article highlights a life-threatening case of DMF-induced takotsubo cardiomyopathy and emphasizes the need for close monitoring of symptoms when initiating disease-modifying drug therapy.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Health Care Sciences & Services
Afshin Derakhshani, Zahra Asadzadeh, Hossein Safarpour, Patrizia Leone, Mahdi Abdoli Shadbad, Ali Heydari, Behzad Baradaran, Vito Racanelli
Summary: Multiple sclerosis is a chronic demyelinating disease characterized by inflammation, and the inhibitory immune checkpoints CTLA-4 and PD-L1 play a crucial role in terminating autoimmune diseases like MS. The study evaluated the gene expression of CTLA-4 and PD-L1 in peripheral blood mononuclear cells of MS patients and investigated the impact of different MS-related treatments on restraining autoreactive T cells to prevent MS autoimmunity.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Clinical Neurology
Anders Svenningsson, Thomas Frisell, Joachim Burman, Jonatan Salzer, Katharina Fink, Susanna Hallberg, Joakim Hambraeus, Markus Axelsson, Faiez Al Nimer, Peter Sundstrom, Martin Gunnarsson, Rune Johansson, Johan Mellergard, Igal Rosenstein, Ahmad Ayad, Irina Sjoblom, Anette Risedal, Pierre de Flon, Eric Gilland, Jonas Lindeberg, Fadi Shawket, Fredrik Piehl, Jan Lycke
Summary: Rifund-MS study provides evidence that rituximab is superior to dimethyl fumarate in preventing relapses in patients with early relapsing-remitting multiple sclerosis. Adverse events such as infusion reactions and gastrointestinal reactions were observed, but there were no safety concerns.
Article
Clinical Neurology
Joao de Sa, Joao Ferreira, Ana M. Macedo
Summary: This study evaluated adherence to dimethyl fumarate (DMF) over 24 months in a cohort of Portuguese patients with multiple sclerosis. The results showed significant adherence to DMF treatment, but the impact of the COVID-19 pandemic on patient follow-up and data collection should be considered.
REVISTA DE NEUROLOGIA
(2023)
Article
Clinical Neurology
Sara Hojjati, Jan Ernerudh, Magnus Vrethem, Johan Mellergard, Johanna Raffetseder
Summary: This study employed targeted proteomics to investigate the effects of DMF treatment on inflammation- and neuro-associated proteins in plasma and cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. The results revealed changes in CSF proteins related to inflammation and neurodegeneration, which could predict treatment response. Protein biomarkers hold promise for personalized medicine.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)